PDK4 and diffuse large B-cell lymphoma: Furthermore, our data showed a metabolic signature of active glycolysis by upregulation of PDK4, indicating that PDK4‐mediated metabolic reprogramming is involved in regulating the glycolysis and rituximab sensitivity of DLBCL cells.